Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B

Dow Jones

2024-11-26

By Dean Seal

Shares of Poseida Therapeutics tripled after the company agreed to be acquired by Roche in a deal worth up to $1.5 billion.

The stock was changing hands at $9.21 in premarket trading on Tuesday. Shares closed yesterday's trading session at $2.86.

The clinical-stage cell and gene therapy company said Tuesday that it would be acquired for about $1 billion, or $9 a share, and additional performance-related payments worth up to $4 a share.

The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies.

Roche is also acquiring Poseida Therapeutics' other cell-therapy candidates as well as related manufacturing capabilities and platform technologies.

The transaction is expected to complete in the first quarter of 2025.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

November 26, 2024 06:52 ET (11:52 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2486076449"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486076449\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486076449?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-26 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486076449","market":"sg","top_or_hot":-1,"title":"Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Poseida <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> tripled after the company agreed to be acquired by Roche in a deal worth up to $1.5 billion. \n</p>\n<p>\n  The stock was changing hands at $9.21 in premarket trading on Tuesday. Shares closed yesterday's trading session at $2.86. \n</p>\n<p>\n  The clinical-stage cell and gene therapy company said Tuesday that it would be acquired for about $1 billion, or $9 a share, and additional performance-related payments worth up to $4 a share. \n</p>\n<p>\n  The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies. \n</p>\n<p>\n  Roche is also acquiring Poseida Therapeutics' other cell-therapy candidates as well as related manufacturing capabilities and platform technologies. \n</p>\n<p>\n  The transaction is expected to complete in the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Poseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPoseida Therapeutics Shares Triple on Roche Acquisition Worth Up to $1.5B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-26 19:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Poseida <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> tripled after the company agreed to be acquired by Roche in a deal worth up to $1.5 billion. \n</p>\n<p>\n  The stock was changing hands at $9.21 in premarket trading on Tuesday. Shares closed yesterday's trading session at $2.86. \n</p>\n<p>\n  The clinical-stage cell and gene therapy company said Tuesday that it would be acquired for about $1 billion, or $9 a share, and additional performance-related payments worth up to $4 a share. \n</p>\n<p>\n  The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies. \n</p>\n<p>\n  Roche is also acquiring Poseida Therapeutics' other cell-therapy candidates as well as related manufacturing capabilities and platform technologies. \n</p>\n<p>\n  The transaction is expected to complete in the first quarter of 2025. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 06:52 ET (11:52 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486076449","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486076449","pubTimestamp":1732621920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Poseida Therapeutics tripled after the company agreed to be acquired by Roche in a deal worth up to $1.5 billion.The stock was changing hands at $9.21 in premarket trading on Tuesday. Shares closed yesterday's trading session at $2.86.The clinical-stage cell and gene therapy company said Tuesday that it would be acquired for about $1 billion, or $9 a share, and additional performance-related payments worth up to $4 a share.The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies.Roche is also acquiring Poseida Therapeutics' other cell-therapy candidates as well as related manufacturing capabilities and platform technologies.The transaction is expected to complete in the first quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","03165":"华夏欧优股对冲","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","PSTX":"Poseida Therapeutics, Inc."},"translate_title":"Poseida Therapeutics股价因收购罗氏而上涨两倍，价值高达$1.5 B","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"LENZ":1,"PSTX":1,"RHHBY":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Poseida Therapeutics tripled after the company agreed to be acquired by Roche in a deal worth up to $1.5 billion. \n\n\n  The stock was changing hands at $9.21 in premarket trading on Tuesday. Shares closed yesterday's trading session at $2.86. \n\n\n  The clinical-stage cell and gene therapy company said Tuesday that it would be acquired for about $1 billion, or $9 a share, and additional performance-related payments worth up to $4 a share. \n\n\n  The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies. \n\n\n  Roche is also acquiring Poseida Therapeutics' other cell-therapy candidates as well as related manufacturing capabilities and platform technologies. \n\n\n  The transaction is expected to complete in the first quarter of 2025. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 06:52 ET (11:52 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}